Concern in India as a double-mutant strain with E484Q and L452R escape mutations has been found in the state of Maharashtra.
A double-mutant strain of SARS-CoV-2 with E484Q and L452R escape mutations has been found in the Indian state of Maharashtra, the country's Ministry of Health and Family Welfare has said. A sharp jump has been seen in COVID-19 cases since mid-February, with Maharashtra accounting for the majority of these.
On 25 March at 8am IST, government data shows an increase of 16,662 COVID-19 cases in a single day in...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
